Circ_0000003 promotes the proliferation and metastasis of non-small cell lung cancer cells via miR-338-3p/insulin receptor substrate 2

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Wei S, Zheng Y, Jiang Y, et al. The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p. EBioMedicine. 2019 Jun;44:182–193.
   PubMed Web of Science ®Google Scholar
• Dubaere E, Goffaux M, Wanet M, et al. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage inon-small celllungcancer. BMC Cancer. 2019 Jun 28;19(1):639.
   PubMedGoogle Scholar
• Antonia SJ, Balmanoukian ABrahmer J, et al. Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC. J Thorac Oncol. 2019 Oct;14(10):1794–1806.
   PubMed Web of Science ®Google Scholar
• Saigi MAlburquerque-Bejar JJ. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. Oncogene. 2019 Aug;38(31):5921–5932.
   PubMed Web of Science ®Google Scholar
• de Fraipont F, Gazzeri S, Cho WC, et al. Circular RNAs and RNA splice variants as biomarkers for prognosis and therapeutic response in the liquid biopsies of lung cancerPatients. Front Genet. 2019 May;7(10):390.
   Google Scholar
• Chi Y, Luo QSong Y, et al. Circular RNA circPIP5K1A promotes non-small cell lung cancer proliferation and metastasis through miR-600/HIF-1α regulation. J Cell Biochem. 2019 Nov;120(11):19019–19030.
   PubMed Web of Science ®Google Scholar
• Wu J, Qi X, Liu L, et al. Emerging epigenetic regulation of circular RNAs in human cancer. Mol Ther Nucleic Acids. 2019 Jun;7(16):589–596.
   Google Scholar
• Maass PG, Glažar P, Memczak S, et al. A map of human circular RNAs in clinically relevant tissues. J Mol Med (Berl). 2017 Nov;95(11):1179–1189.
   PubMed Web of Science ®Google Scholar
• Verduci L, Strano S, Yarden Y, et al. ThecircRNA-microRNA code: emerging implications forcancerdiagnosisand treatment. Mol Oncol. 2019 Apr;13(4):669–680.
   PubMed Web of Science ®Google Scholar
• Li Y, Hu J, Li L, et al. Upregulated circular RNA circ_0016760 indicates unfavorable prognosis inNSCLCand promotes cell progression through miR-1287/GAGE1 axis. Biochem Biophys Res Commun. 2018 Sep 10;503(3):2089–2094.
   PubMed Web of Science ®Google Scholar
• Chang H, Qu J, Wang J, et al. Circular RNA circ_0026134 regulates non-small cell lung cancer cell proliferation and invasion via sponging miR-1256 and miR-1287. Biomed Pharmacother. 2019 Apr;112:108743.
   PubMed Web of Science ®Google Scholar
• Cui J, Li W, Liu G, et al. A novel circular RNA, hsa_circ_0043278, acts as a potential biomarker and promotes non-small cell lung cancer cell proliferation and migration by regulating miR-520f. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):810–821.
   PubMed Web of Science ®Google Scholar
• Wang J, Li H. CircRNAcirc_0067934silencing inhibits the proliferation, migration and invasion ofNSCLCcells and correlates with unfavorable prognosis inNSCLC. Eur Rev Med Pharmacol Sci. 2018 May;22(10):3053–3060.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao H, Zhang L. Identification of the tumor-suppressive function of circular RNA FOXO3 in non-small cell lung cancer through sponging miR-155. Mol Med Rep. 2018 Jun;17(6):7692–7700.
   PubMed Web of Science ®Google Scholar
• Lee SS, Cheah YK. The interplay betweenmicrornasand cellular components of Tumour Microenvironment (TME) on Non-Small-CellLungCancer (NSCLC) progression. J Immunol Res. 2019 Feb;13:3046379.
   Google Scholar
• Cui M, Yao X, Lin Y, et al. Interactive functions ofmicroRNAsin the miR-23a-27a-24-2 cluster and the potential for targeted therapy incancer. J Cell Physiol. 2019 Jun 13; DOI:10.1002/jcp.28958
   Web of Science ®Google Scholar
• Zhang M, Shi H, Zhang C, et al. MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4807–4814.
   PubMed Web of Science ®Google Scholar
• Shi J, Ma H, Wang H, et al. Overexpression of LINC00261 inhibits non-small cell lung cancer cells progression by interacting with miR-522-3p and suppressing Wnt signaling. J Cell Biochem. 2019 Jun 12; DOI:10.1002/jcb.29149
   Web of Science ®Google Scholar
• Zhang P, Guoguang S, Xingyu L, et al. MiR-338-3pinhibits the growth and invasion of non-small cell lung cancer cells by targetingIRS2. Am J Cancer Res. 2017;7(1):53–63.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao F, Cai S, et al. MiR-193a regulates chemoresistance of human osteosarcoma cells via repression ofIRS2. J Bone Oncol. 2019 May 11;17:100241.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li Z, Chen Y, et al. MicroRNA-766 inhibits papillary thyroidcancerprogression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway. Int J Oncol. 2019 Jan;54(1):315–325.
   PubMed Web of Science ®Google Scholar
• Jeong SH, Kim HB, Kim MC, et al. Hippo-mediated suppression ofIRS2/AKT signaling prevents hepatic steatosis and livercancer. J Clin Invest. 2018 Mar 1;128(3):1010–1025.
   PubMed Web of Science ®Google Scholar
• Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker forcancer. Mol Cancer. 2017 May 23;16(1):94.
   PubMed Web of Science ®Google Scholar
• Chinniah C, Aguarin LCheng P, et al. Early detection of recurrence in patients with locally advanced non-small-cell lung cancer via circulating tumor cell analysis. Clin Lung Cancer. 2019 Sep;20(5):384–390.e2.
   Google Scholar
• Kowanetz M, Zou W, Gettinger SN, et al. Differential regulation of PD-L1 expression by immune and tumor cells inNSCLCand the response totreatmentwith atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119–E10126.
   PubMed Web of Science ®Google Scholar
• Sun H, Xi P, Sun Z, et al. Circ-SFMBT2promotestheproliferationofgastriccancercellsthroughspongingmiR-182-5ptoenhanceCREB1expression. Cancer Manag Res. 2018 Nov;16(10):5725–5734.
   Google Scholar
• Chen S, Li T, Zhao Q, et al. Using circular RNA hsa_circ_0000190 as a new biomarker in thediagnosisof gastric cancer. Clin Chim Acta. 2017 Mar;466:167–171.
   PubMed Web of Science ®Google Scholar
• Hentze MW, Preiss T. Circular RNAs: splicing’s enigma variations. Embo J. 2013 Apr 3;32(7):923–925.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Jiang LH, Sun DW, et al. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018 Jan;25(1):1–7.
   PubMed Web of Science ®Google Scholar
• Zhou X, Natino D, Qin Z, et al. Identification and functional characterization of circRNA-0008717 as an oncogene in osteosarcoma through sponging miR-203. Oncotarget. 2017 Dec 20;9(32):22288–22300.
   PubMedGoogle Scholar
• Kristensen LS, Hansen TB, Venø MT, et al. Circular RNAs incancer: opportunities and challenges in the field. Oncogene. 2018 Feb 1;37(5):555–565.
   PubMed Web of Science ®Google Scholar
• Longqiang W, Tong X, Zhengyu Z, et al. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ innon-small celllungcancer. Mol Cancer. 2018 Sep 27;17:140. Published online.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F, Nopora A. MicroRNAs as potential targets for therapeutic intervention with metastasis of non-small cell lung cancer. Cancer Genomics Proteomics. 2019 Mar - Apr;16(2):99–119.
   PubMed Web of Science ®Google Scholar
• Szejniuk WM, Robles AI, McCulloch T, et al. Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art. Pharmacogenomics J. 2019 Feb;19(1):5–14.
   PubMed Web of Science ®Google Scholar
• Zhang R, Shi H, Ren F, et al. Down-regulation ofmiR-338-3p and up-regulation of macc1 indicated poor prognosis of epithelial ovarianCancerPatients. JCancer. 2019 Feb 23;10(6):1385–1392.
   PubMed Web of Science ®Google Scholar
• Li M, Bian Z, Jin G, et al. LncRNA-SNHG15 enhances cell proliferation in colorectalcancerby inhibitingmiR-338-3p. CancerMed. 2019 May;8(5):2404–2413.
   Google Scholar
• Ding Z, Zhu J, Zeng Y, et al. The regulation of neuropilin 1 expression bymiR-338-3p promotesnon-small celllungcancer via changes in EGFR signaling. Mol Carcinog. 2019 Jun;58(6):1019–1032.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zheng H, Zhang G, et al. MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2. Cancer Cell Int. 2017 Apr 17;17:46.
   PubMed Web of Science ®Google Scholar
• Machado-Neto JA, Fenerich BA, Rodrigues Alves APN, et al. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics (Sao Paulo). 2018 Oct 11;73(suppl 1):e566s.
   PubMedGoogle Scholar
• Zhu S, Ward BM, Yu J, et al. IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma. JCI Insight. 2018 Apr 19;3(8): pii: 97398.
   Web of Science ®Google Scholar
• Liu H, Ren G, Zhu L, et al. The upregulation of miRNA-146a inhibited biological behaviors of ESCC through inhibition of IRS2. Tumour Biol. 2016 Apr;37(4):4641–4647.
   PubMedGoogle Scholar
• Park DH, Jeon HS, Lee SY, et al. MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2. Int J Oncol. 2015 Oct;47(4):1545–1553.
   PubMed Web of Science ®Google Scholar
• Gao J, Feng X, Wang F, et al. microRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2. 2019 Aug;120(8):13453–13463.
   Google Scholar